Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7625567: Induction of immune responses to isoaspartyl-modified antigens

Share

Filing Information

Inventor(s) Mark J. Mamula ·
Assignee(s) Yale University ·
Attorney/Agent(s) Todd E. Garabedian · Wiggin and Dana LLP ·
Primary Examiner Karen A Canella ·
Application Number US10613272
Filing date 07/03/2003
Issue date 12/01/2009
Predicted expiration date 11/13/2024
Patent term adjustment 1044
U.S. Classifications 424/204.1  · 530/402  · 424/277.1  · 530/403  · 424/234.1  ·
International Classifications A61K3900  · A61K3902  · A61K3912  · C08H100  ·
Kind CodeB1
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a Continuation-in-Part of International Application No. PCT/US02/00336, filed Jan. 4, 2002, which claims the benefit of U.S. Provisional Application No. 60/259,765 filed Jan. 4, 2001. These applications are herein incorporated by reference in their entireties.
10 Claims, 9 Drawings


Abstract

The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as antibodies reactive with the isoaspartyl-modified proteins, peptides, or cells.

Independent Claims | See all claims (10)

  1. 1. A method of enhancing the humoral immune response of a patient relative to the normal humoral immune response, comprising the steps of: growing cells containing a tumor antigen, a bacterial protein, or a viral protein under conditions wherein an aspartic acid residue or an asparigine residue in said tumor antigen, said bacterial protein, or said viral protein is converted to an isoaspartic acid residue to produce an isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein, said conditions comprising exposing said cells to 15-30 μM adenosine dialdehyde at approximately 25-40° C. for 1-5 days; optionally isolating said isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein; and administering said cells or said isolated isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, or an isoaspartic acid-containing viral protein to said patient to enhance the humoral immune response of said patient.
  2. 6. A method of enhancing the humoral immune response of a patient relative to the normal humoral immune response, comprising the steps of: providing a tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof, wherein each of said tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof comprises an aspartic acid residue or an asparigine residue; treating said tumor antigen, a bacterial protein, or a viral protein, or a fragment thereof to convert said aspartic acid residue or said asparigine residue to an isoaspartic acid residue to produce an isoaspartic acid-containing tumor antigen, an isoaspartic acid-containing bacterial protein, an isoaspartic acid-containing viral protein, or isoaspartic acid-containing fragment thereof; assaying for levels of isoaspartyl modification in the treated tumor antigen, bacterial protein, viral protein, or fragment thereof; administering the isoaspartic acid-containing tumor antigen, isoaspartic acid-containing bacterial protein, isoaspartic acid-containing viral protein, or isoaspartic acid-containing fragment thereof to said patient to elicit said enhanced humoral immune response.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5169862* Peptide Technologies Corporation Burke et al. Dec 1992
US5298490* Immunobiology Research Institute, Inc. Heavner et al. Mar 1994
US5565202* The United States of America as represented by the Secretary of Agriculture Witter Oct 1996
US5582831 Yeda Research and Development Co., Ltd. Shinitzki Dec 1996
US5733540 Lee Mar 1998
US5872104 Oridigm Corporation Vermeulen et al. Feb 1999
US5965381 Ludwig Institute for Cancer Research Bruggen et al. Oct 1999
US6812023* Anosys, Inc. Lamparski et al. Nov 2004

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
WO199733612Sep 1997
WO199734613*Sep 1997
* cited by examiner

Other Publications

Bodey et al, (Anticancer Research, 2000, vol. 20, pp. 2665-2676).*
Schultze et al (Trends in Immunology, 2004, vol. 25, pp. 659-664).*
Addissson et al (PNAS, vol. 92, pp. 8522-8526).*
Le Fur et al (PNAS, 1997, vol. 94, pp. 7561-7565).*
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).*
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-724.*
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).*
Ramakrishna and Shinitzky (Cancer Immunol Immunother, 1991, vol. 33, pp. 1-8).*
Desrivieres et al (JBC, 1997, vol. 272, pp. 2470-2476).*
Azorsa et al (Blood, 1991, vol. 78, pp. 280-284).*
Mamula, Immunological Rev, 1998, vol. 164, pp. 231-239.*
Mamula et al, J Biol Chem, 1999, vol. 274, pp. 22321-22327.*
Aswad et al (Journal of Pharmaceutical and Biomedical Analysis, 2000, vol. 21, pp. 1129-1136).*
Nossal, Annual Review in Immunology, 1983, vol. 1, pp. 33-62.*
Sabin et al, JAMA, 1984, vol. 251, pp. 2988-2993.*
Lycke et al, Sandinavian Journal of Immunology, 1987, vol. 25, pp. 407-412.*
Smith et al (Immunology, 2002, vol. 106, pp. 144-158).*
Mamula et al (Journal of Biological Chemistry, 1999, vol. 274, pp. 22321-22327).*
The abstract of Disis et al (Critical Reviews in Immunology, 1998, vol. 18, pp. 37-45).*
Gene Bank Accession No. BAA32580, Nov. 9, 2007.*
Ryttersgaard, C., et al., “Crystal Structure of Human L-Isoaspartyl Methyltransferase,” J. Biol. Chem. 277:10642-10646. (Mar. 22, 2002), The American Society for Biochemistry and Molecular Biology, Inc. (published online Jan. 2002).
* cited by examiner

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.